Budget Impact of the Oncotype DX Breast Recurrence Score® Test in Patients with Early Primary Hormone-Receptor-Positive, HER2-Negative, Node-Positive Breast Cancer in Germany
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
View abstract on PubMed
Summary
This summary is machine-generated.The Oncotype DX Breast Recurrence Score test can reduce healthcare costs for node-positive breast cancer patients in Germany. This gene expression test helps avoid unnecessary chemotherapy, leading to significant cost savings and improved patient quality of life.
Area Of Science
- Oncology
- Health Economics
Background
- Gene expression tests guide chemotherapy decisions in early HR+, HER2- breast cancer.
- These tests are reimbursed for lymph node-negative (pN0) patients in Germany.
- A budget impact model assessed the Oncotype DX Breast Recurrence Score test for node-positive (pN1) patients.
Purpose Of The Study
- To evaluate the budget impact of using the Oncotype DX Breast Recurrence Score test in node-positive (pN1) early breast cancer patients in Germany.
- To analyze cost-effectiveness from a sickness fund perspective.
- To determine if the test can reduce overall healthcare expenditure.
Main Methods
- A budget impact model was developed.
- Calculated average total cost per node-positive patient versus no testing.
- Incorporated costs of chemotherapy, side effects, and distant metastasis treatment.
- Performed probabilistic multivariate sensitivity analysis to assess result stability.
Main Results
- The Oncotype DX Breast Recurrence Score test resulted in average savings of EUR 4,272 per node-positive patient after deducting test costs.
- Savings from avoiding chemotherapy and side effect treatments averaged EUR 6,677.
- Targeted chemotherapy use led to slightly lower costs for treating distant metastasis.
- Sensitivity analysis confirmed predominantly cost savings.
Conclusions
- The Oncotype DX Breast Recurrence Score test reduces healthcare costs in Germany for node-positive (pN1) patients.
- The test minimizes both unnecessary chemotherapy and undertreatment.
- Benefits include reduced patient morbidity and improved quality of life.
These videos have been matched automatically. Contact us if they are not relevant.
These videos have been matched automatically. Contact us if they are not relevant.
